Inno-PD Capsule SR is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed for the management of gastrointestinal disorders characterized by acid reflux, dyspepsia, and delayed gastric emptying. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, providing symptomatic relief in conditions like gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The sustained-release (SR) formulation ensures prolonged therapeutic plasma concentrations, enhancing patient compliance and clinical efficacy. Inno-PD Capsule SR is indicated for patients requiring combined prokinetic and acid-suppressive therapy, particularly in cases where monotherapy is insufficient. The medication should be administered as prescribed by a healthcare professional, with attention to contraindications such as known hypersensitivity to either component, underlying cardiac arrhythmias, or concurrent use of QT-prolonging drugs. Common adverse effects may include headache, dry mouth, and abdominal discomfort. Regular monitoring and adherence to dosing guidelines are recommended to optimize therapeutic outcomes and minimize potential risks.